← TrialMatch
HomeTrials

Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Mali

Sinonasal mucosal malignant melanoma (SNMM) is a nasal and paranasal sinus malignancy with a low incidence and extremely poor prognosis, exhibiting specificity in Asian populations. For resectable SNMM, the efficacy of neoadjuvant immunotherapy is unclear. This prospective clinical study aims to explore the survival pr

Condition(s)Mucosal Melanoma of the Head and Neck
StatusRecruiting
PhasePhase 2
Study typeInterventional
SummarySinonasal mucosal malignant melanoma (SNMM) is a nasal and paranasal sinus malignancy with a low incidence and extremely poor prognosis, exhibiting specificity in Asian populations. For resectable SNMM, the efficacy of neoadjuvant immunotherapy is unclear. This prospective clinical study aims to explore the survival prognosis of neoadjuvant immunotherapy combing radiochemotherapy after Endoscopic Surgery for resectable SNMM.
Who can participateInclusion Criteria: * Histopathologically confirmed diagnosis of malignant melanoma of the nasal cavity and paranasal sinuses. * T stage of T3 or T4a. * Age ≥18 years. * No distant metastasis. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, with general condition tolerating chemotherapy and general anesthesia for surgery. * Locally resectable with curative intent, and able to undergo contrast-enhanced CT or contrast-enhanced MRI examinations. * Adequate organ function: Hematology: white blood cells ≥3.0 × 10\^9/L; absolute neutrophil count ≥1.5 × 10\^9/L; hemoglobin ≥80 g/L; platelets ≥100 × 10\^9/L. Hepatic function: total bilirubin ≤1.5 × upper limit of normal (ULN); AST and ALT ≤3 × ULN. Coagulation: international normalized ratio (INR) or prothrombin time
Ages18 Years
SexAll
Lead sponsorEye & ENT Hospital of Fudan University
LocationsShanghai, Shanghai Municipality, China
Start date2023-06-01
NCT IDNCT07614828
Official listinghttps://clinicaltrials.gov/study/NCT07614828

🔍 Search all trials →